Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Am J Med Genet A ; 182(7): 1562-1571, 2020 07.
Article in English | MEDLINE | ID: mdl-32426895

ABSTRACT

We report on a 26-year-old male with extreme short stature, microcephaly, macroglossia, other dysmorphic features, severe intellectual disability, and a bone dysplasia. The patient had an extensive genetic and biochemical evaluation that was all normal or noninformative. Recently, the proband died following a period of not eating. He likely had a previously undescribed syndrome of unknown etiology.


Subject(s)
Abnormalities, Multiple/etiology , Bone Diseases, Developmental/etiology , Dwarfism/etiology , Adult , Bone Diseases, Developmental/diagnostic imaging , Face/abnormalities , Female , Fetal Growth Retardation , Humans , Infant, Newborn , Intellectual Disability , Male , Microcephaly/etiology , Pregnancy , Syndrome
2.
Child Neurol Open ; 8: 2329048X211036137, 2021.
Article in English | MEDLINE | ID: mdl-34423068

ABSTRACT

Huntington disease (HD) is caused by a pathologic cytosine-adenine-guanine (CAG) trinucleotide repeat expansion in the HTT gene. Typical adult-onset disease occurs with a minimum of 40 repeats. With more than 60 CAG repeats, patients can have juvenile-onset disease (jHD), with symptom onset by the age of 20 years. We report a case of a boy with extreme early onset, paternally inherited jHD, with symptom onset between 18 and 24 months. He was found to have 250 to 350 CAG repeats, one of the largest repeat expansions published to date. At initial presentation, he had an ataxic gait, truncal titubation, and speech delay. Magnetic resonance imaging showed cerebellar atrophy. Over time, he continued to regress and became nonverbal, wheelchair-bound, gastrostomy-tube dependent, and increasingly rigid. His young age at presentation and the ethical concerns regarding HD testing in minors delayed his diagnosis.

3.
J Child Neurol ; 36(1): 65-78, 2021 01.
Article in English | MEDLINE | ID: mdl-32875938

ABSTRACT

Leukodystrophies are a group of neurodegenerative genetic disorders that affect approximately 1 in 7500 individuals. Despite therapeutic progress in individual leukodystrophies, guidelines in neurologic care are sparse and consensus among physicians and caregivers remains a challenge. At patient advocacy meetings hosted by Hunter's Hope from 2016-2018, multidisciplinary experts and caregivers met to conduct a literature review, identify knowledge gaps and summarize best practices regarding neurologic care. Stages of severity in leukodystrophies guided recommendations to address different levels of need based on a newly defined system of disease severity. Four core neurologic domains prioritized by families were identified and became the focus of this guideline: sleep, pain, seizures/epilepsy, and language/cognition. Based on clinical severity, the following categories were used: presymptomatic, early symptomatic, intermediate symptomatic, and advanced symptomatic. Across the leukodystrophies, neurologic care should be tailored to stages of severity while accounting for unique aspects of every disease and multiple knowledge gaps present. Standardized tools and surveys can help guide treatment but should not overburden families.


Subject(s)
Hereditary Central Nervous System Demyelinating Diseases/therapy , Child , Humans , Patient Advocacy , Practice Guidelines as Topic , Severity of Illness Index
SELECTION OF CITATIONS
SEARCH DETAIL